Vaxart Raises $12.5M to Progress Oral Vaccine for Avian Flu
Summary
Vaxart closed a $12.5 million Series B round to advance its oral vaccine for avian influenza into Phase I trials. The company’s platform uses a TLR3-targeting adjuvant designed to trigger an immune response in the gastrointestinal tract. That approach lets patients take vaccines in pill form instead of by injection. Vaxart says the same vector can support multiple vaccines, which could lower cost and regulatory complexity across its pipeline. Care Capital led the round, and its representatives joined Vaxart’s board.
Funding
Amount
$12.5M
Total raised
Date
March 4, 2010
Announcement date
Investors
Care Capital
Lead investors
Company
http://vaxart.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected